Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Reconsiders UDI Direct Marking Requirements For Implants

This article was originally published in The Gray Sheet

Executive Summary

An agency official says FDA is reworking the UDI direct part marking requirements for implants and making other changes in the final unique device identification rule, due out in June.

Advertisement

Related Content

FDA Issues UDI Final Rule, Removes Direct Marking Requirement For Implants
Cap On Mini-Sentinel Funds Raised To $135 Mil. To Support Powerful Surveillance Resource
CDRH Details Path Forward For National Post-Market Surveillance System
FDA To Issue UDI Database Draft Guidance In March
UDIs And Adverse Events Draw Attention In Electronic Record Meaningful Use Comments
Industry, Hospital Groups Debate Implementation Deadlines For UDI Rule
Midwest Hospitals Prepare For Stent Unique-Device-Identifier Demo

Topics

Advertisement
UsernamePublicRestriction

Register

MT032012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel